Author name: Kim Dang

Adelaide, South Australia, September 25, 2024/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer EnGeneIC Pty Ltd., for a project including technology transfer, process scale-up and GMP batch manufacture of EnGeneIC’s proprietary ‘EnGeneIC Dream Vector’ (EDV™) nanocells.    EnGeneIC’s mission is to […]

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx Adelaide, South Australia, June 3, 2024/– BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to utilize CelluTx’s Recombination Based Plasmid System (RBPS) technology with BioCina’s CDMO clients. RBPS is a cutting-edge technology

Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors  (Miami and Perth, Australia, March 5, 2024) Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment of Mark W. Womack as a Director of the Board. “We are thrilled to have Mark

ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers. This alliance enables BioCina to offer the highest quality fill-and-finish solutions to